Short Interest in UCB SA (OTCMKTS:UCBJY) Increases By 363.3%

UCB SA (OTCMKTS:UCBJY) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 13,900 shares, a growth of 363.3% from the February 13th total of 3,000 shares. Based on an average trading volume of 92,400 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.0% of the company’s shares are sold short.

UCB Price Performance

OTCMKTS UCBJY traded down $0.39 during trading on Friday, hitting $98.11. The stock had a trading volume of 102,733 shares, compared to its average volume of 42,905. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The firm has a 50 day moving average price of $97.56 and a 200 day moving average price of $95.27. UCB has a twelve month low of $56.77 and a twelve month high of $106.60.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.